Oral solid dose production facility
Eisai China has built a new oral solid dose (OSD) production facility at its new Suzhou plant in China.
The new OSD production facility replaces an existing building at the Suzhou site.
A ground-breaking ceremony for the project took place in May 2016 while construction was completed in January 2018. The full-scale operation of the new facility started in November 2018.
The new facility enables Eisai to strengthen its in-house domestic production system in China.
The new OSD facility is located near the 168 Xingpu Road within the Suzhou Industrial Park, which is situated in the Chinese coastal province of Jiangsu, Suzhou.
The Suzhou Industrial Park is an economic co-operation project between China and Singapore. It covers a 288km² area and provides easy access to various rail and motorway networks.
The new OSD production facility is five times bigger than the existing plant. It includes three floors with a total floor space of 20,240m².
The plant is designed and built according to Chinese good manufacturing practices (GMP) and international GMP standards. It also includes energy-saving features.
It supplies Eisai China’s high-quality products to the Chinese market and other Asian countries in the future.
Eisai’s new Suzhou plant is built on a total site area of 134,000m². It comprises the OSD facility, an administration building and a parenteral production facility.
Construction of the parenteral production facility was completed in November 2014. The two-storey facility covers an area of 5,690m² and manufactures the injection formulation Methycobal®.
The administration building is a two-storey facility with a floor space of 2,230m². It features offices, meeting rooms and a cafeteria. The distribution warehouse, featuring a single floor, covers a total floor space of approximately 7,812m2.
The new OSD facility is expected to serve as a global innovation centre for Eisai in the future.
The new oral solid dose facility is capable of handling the formulation and packaging of OSD products such as Methycobal®, Aricept® and Pariet® for the Chinese market. It is also involved in the packaging of imported products.
The production capacity of the facility is more than double that of the existing plant in Suzhou. The new facility has an annual production capacity of three billion formulated tablets and packaging capacity of five billion tablets.
Founded in 1996, Eisai China is a pharmaceutical materials manufacturing company and a wholly owned subsidiary of Eisai Co, which is based in Tokyo, Japan.
Eisai began expanding to China with the establishment of Shenyang Eisai Pharmaceutical. This was followed by Eisai Suzhou Pharmaceutical in Suzhou Industrial Park, which is now named Eisai China.
Eisai China promotes more than ten medicines in China, covering the central nervous system (CNS), the digestive system and the endocrine and orthopaedics systems.
The new OSD facility enables the company to meet the growing demand for its OSD products while improving production efficiency and expanding its pharmaceutical supply chain.
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Merck announced the expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) production capabilities and capacity at…
Alnylam Pharmaceuticals is constructing a new drug substance manufacturing and cGMP warehouse facility in Norton, Massachusetts, US. The company broke…
POINT Biopharma, a clinical-stage biopharmaceutical company, is planning to construct its first US manufacturing plant in Indianapolis, Indiana. The investment…